TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are at least 18 years old, underwent cardiac surgery in Harapan Kita National Cardiovascular Center from January 2020 to December 2022.~2. Patients with condition was complicated with Acute Kidney Injury (AKI) which was characterised by an increase in serum creatinine \> 0.3 mg/dL or \> 150% of the preoperative serum creatinine value, which was checked within 12 hours post-operative.~3. All patients' data is recorded in the medical records unit.~Exclusion Criteria:~1. Patients with previous history of dialysis or renal failure in dialysis.~2. Incomplete or loss of patients' data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AKI-RRT (Type: None): Post cardiovascular surgery patients with condition of acute kidney injury postoperative; and with an exposure of renal replacement therapy (intermittent haemodialysis or continuous renal replacement therapy) which is indicated postoperatively.
- AKI non RRT (Type: None): Post cardiovascular surgery patients with condition of acute kidney injury postoperative; but without exposure of renal replacement therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug.~* Moderate to severe chronic plaque psoriasis at both Screening and Baseline (Randomization) Visits~* Candidates for systemic therapy or phototherapy for psoriasis treatment as assessed by the investigator~Exclusion Criteria:~* Prior therapy with an anti-interleukin (IL)-17 or anti-IL12/23p40 or anti-IL-23p19 inhibitor~* Concurrent therapy with a biologic and/or other systemic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for risankizumab by subcutaneous (SC) injection.
- Risankizumab (Type: EXPERIMENTAL): Risankizumab by subcutaneous (SC) injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must give written informed consent before any assessment is performed.~2. Patients with mild to moderate essential hypertension, untreated or currently taking antihypertensive therapy (mean sitting diastolic blood pressure ≥ 95 mmHg and \< 110 mmHg, and mean sitting systolic blood pressure ≥ 140 mmHg and \< 180 mmHg).~3. Patients must be willing and able to undergo ambulatory blood pressure monitoring for a 24-hr period at the beginning and the end of the 8-week treatment.~4. Patient must be able to communicate and comply with all study requirements and demonstrate good medication compliance.~Exclusion Criteria:~1. Patients with severe hypertension.~2. Patients with history of angioedema, drug-related or otherwise~3. Pregnant or nursing women~4. Women of child-bearing potential , who do not use adequate birth control methods~5. History or evidence of a secondary form of hypertension.~6. History of angina pectoris, myocardial infarction, coronary bypass surgery, ischemic heart disease, surgical or percutaneous arterial intervention of any kind, stroke, TIA, carotid artery stenosis, aortic aneurysm, or peripheral arterial disease.~7. Diabetes mellitus.~8. Previous or current diagnosis of heart failure (NYHA Class II-IV).~9. Clinically significant valvular heart disease at the time of screening.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 100 mg (Type: EXPERIMENTAL): LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
- LCZ696 200 mg (Type: EXPERIMENTAL): LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
- LCZ696 400 mg (Type: EXPERIMENTAL): LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zilver PTX Delivery System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has symptomatic vascular disease of the native above-the-knee femoropopliteal arteries~* Patient has atherosclerotic lesion of the above-the-knee femoropopliteal artery~Exclusion Criteria:~* Patient is \< 18 years of age~* Patient unable to complete required follow-up assessments~* Patient unwilling to sign and date the informed consent~* Simultaneous participation in another investigational drug or device study~* Pregnant, breastfeeding or planning to become pregnant in the next 5 years~* Additional medical/anatomical restrictions as specified in the Clinical Investigation Plan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Eluting Stent (Type: EXPERIMENTAL): Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with pressure ulcers stage II, III or IV, non-healing admitted to Changi General Hospital for \> 2 weeks~* Patients who are able to attend outpatient follow-up appointments for dietary and wound review~Exclusion Criteria:~* Age \< 21 years old~* Poorly controlled Diabetic Patients (HbA1c \>7.0%)~* Patients on Total Parenteral Nutrition~* Patients in MICU/ SICU/ Medically Unstable/ Palliative Care~* Patients with severe Sepsis~* Length of stay \< 2 weeks~* Patients who require fluid restriction \< 1L/d~* Patients on any other wound healing supplements (e.g. Zinc, Vitamin A and Vitamin C)~* Patients with lower extremity ulcers with untreated peripheral vascular disease~* Patients with deep tissue infection and/or requiring debridement of necrotic or sloughy tissue~* Patients unable to attend outpatient follow-up appointments~* Patients who cannot tolerate oral intake \> 70% EER and/or Fluid intake 30ml/kg BW~* Patients who require protein restriction~* Patients who are unable to give consent (absence of next-of-kin)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abound (Type: EXPERIMENTAL): Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator that contains none of the active ingredients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 5-49 years of age~* Members of the Kaiser Permanente (KP) Health Care Plan within KP of Northern California, KP of Colorado, and KP of Hawaii~Exclusion Criteria:~* Must not have had any high risk underlying medical conditions, includig asthma

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): 5-8 years of age, estimated to be approximately 4,000 new FluMist vaccinees per season
- 2 (Type: None): 9-17 years of age, estimated to be approximately 5,000 new FluMist vaccinees per season
- 3 (Type: None): 18-49 years of age, estimated to be approximately 6,000 new FluMist vaccinees per season.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Includes:~* The patient has a documented diagnosis and clinical manifestation of type 1 Gaucher disease~* The patient is at least 2 years of age.~* The patient has not received treatment for Gaucher disease (investigational products, miglustat, or imiglucerase) within 12 months prior to study entry, as documented in the patient's medical history.~* Female patients of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study and must have negative results to a pregnancy test performed at the time of enrollment and as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy.~* The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).~* The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator.~Exclusion Criteria~Includes:~* The patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease.~* The patient has received treatment with any non-Gaucher disease-related investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted.~* The patient is known to be positive for human immunodeficiency virus (HIV).~* The patient is known to be positive for hepatitis B and/or C.~* The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study.~* The patient has a significant comorbidity(ies) that might affect study data or confound the study results (e.g., malignancies, primary biliary cirrhosis, autoimmune liver disease, etc.).~* The patient is unable to comply with the protocol, e.g., has a clinically relevant medical condition making implementation of the protocol difficult, has an uncooperative attitude, is unable to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GA-GCB (Type: EXPERIMENTAL): VPRIV™ ,velaglucerase alfa
- imiglucerase (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be ≥18 and ≤90 years of age~* Female patients can participate if they are surgically sterile or completed menopause or females capable of having children and agree not to attempt pregnancy while receiving IV study therapy and for a period of 7 days after~* Patient has a ceftazidime-resistant Gram negative pathogen that was isolated from an appropriate culture within 5 days prior to study entry (ie, within 5 days prior to Screening; the study-qualifying culture), which was determined to be the causative agent of the entry infection~Exclusion Criteria:~* Patient has an APACHE II score \>30 (cIAI patients only)~* Patient has an infection due to Gram negative pathogen that is unlikely to respond to CAZ-AVI treatment (eg, Acinetobacter spp., Stenotrophomonas spp.)~* Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant Patient is immunocompromised~* Patient has a rapidly progressive or terminal illness with a high risk of mortality due to any cause, including acute hepatic failure, respiratory failure or severe septic shock such that they are unlikely to survive the 4- to 5-week study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ceftazidime - Avibactam ( CAZ-AVI) (Type: EXPERIMENTAL): IV treatment
- Best Available Therapy (Type: ACTIVE_COMPARATOR): IV treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients who have been diagnosed with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) by physician and need relief of various symptoms associated with Long Acting Beta2 Agonist (LABA) or Long Acting Muscarinic Antagonist (LAMA).~* Patients who are prescribed Tio+Olo FDC 5µg/5µg for the first time~Exclusion criteria:~* Patients who have been registered once in this study (i.e., re-entry of patients is not allowed).~* Patients who are participating in a registry or clinical trial.~* Patients who have a contraindication to Tio+Olo FDC 5µg/5µg defined in the package insert for Tio+Olo FDC 5µg/5µg.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spiolto (Type: None): Patient with COPD to received Spiolto

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy White, male volunteers between 18 and 55 years of age (inclusive).~* BMI between 19 and 28 kg/m² (inclusive).~Exclusion Criteria:~* Previous participation in a clinical study with rotigotine~* History or current condition of epilepsy and/or seizures.~* Known clinically relevant allergy or known/suspected clinically relevant drug hypersensitivity.~* History of significant skin hypersensitivity to adhesives or other transdermal products or recently unresolved contact dermatitis.~* History or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease.~* Clinically relevant abnormality in physical examination, ECG, vital signs or safety laboratory examinations.~* Positive HIV, hepatitis B or C test or positive alcohol or drug test.~* Relevant hepatic or renal dysfunction~* Intake of medication that might interfere with the test drug within 2 weeks prior to dosing.~* Thickly hair-covered abdomen resulting in difficulties in finding appropriate patch application sites

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Sequence A-B (Test: PR2.1.1 - Reference: PR1.0) (Type: EXPERIMENTAL): Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days
- Sequence B-A (Reference: PR1.0 - Test: PR2.1.1) (Type: EXPERIMENTAL): Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meets I-SPY 2 TRIAL inclusion criteria~  * High-risk for recurrent disease~PATIENT CHARACTERISTICS:~* Able to tolerate imaging required by protocol~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diffusion Weighted-MRI (Type: EXPERIMENTAL): Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Loading in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* COPD diagnosis according GOLD criteria~* Men between 45 and 80 years old~Exclusion Criteria:~* History of asthma or atopy, renal failure, heart failure, arrhythmias or cardiac electrical disturbances, and other significant disease other than COPD.~* Individuals on chronic oral steroids, diuretics, or use of mineral supplementation.~* Locomotor impairment.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 to 70 years, inclusive, with migraine onset at ≤50 years of age~* Patient signs and dates the informed consent document~* Patient has history of migraine according to International Classification of Headache Disorders, or clinical judgment suggests a migraine diagnosis~* 85% e-diary compliance~* Total body weight between 99 and 265 lbs, inclusive~  * Additional criteria apply, please contact the investigator for more information~Exclusion Criteria:~* Clinically significant hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary, neurologic, hepatic, or ocular disease, at the discretion of the investigator~* Evidence or medical history of clinically significant psychiatric issues, including any suicide attempt in the past, or suicidal ideation with a specific plan in the past 2 years~* History of clinically significant cardiovascular disease or vascular ischemia (such as myocardial, neurological \[eg, cerebral ischemia\], peripheral extremity ischemia, or other ischemic event) or thromboembolic events (arterial or venous thrombotic or embolic events), such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism~* Known infection or history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection~* Past or current history of cancer in the last 5 years, except for appropriately treated nonmelanoma skin carcinoma~* Pregnant or nursing females~* History of hypersensitivity reactions to injected proteins, including monoclonal antibodies~* Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months or 5 half-lives, whichever is longer~  * Additional criteria apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo
- Fremanezumab 675 mg/placebo/placebo (Type: EXPERIMENTAL): Participants randomized to receive fremanezumab 675 mg/placebo/placebo received 675 mg of fremanezumab as 3 injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
- Fremanezumab 225/225/225 mg (Type: EXPERIMENTAL): Participants randomized to receive fremanezumab 225/225/225 mg received 1 active injection (225 mg/1.5 mL) on Days 0, 28 and 56.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete